Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nichi-Iko Seeks To Acquire Teikoku Medix To Be Largest Japanese Generic

This article was originally published in PharmAsia News

Executive Summary

Nichi-Iko Pharmaceutical plans to acquire Teikoku Medix, also of Japan, in a bid to become the largest maker of generic drugs in the country. The Nichi-Iko plan is to make the move as early as this summer and turn the Teikoku unit into a wholly owned subsidiary. The value of Teikoku Medix stock, owned by Teikoku Seiyaku, is estimated at about $70 million. The planned merger would combine sales worth $424 million, more than any other generic in Japan. (Click here for more - a subscription may be required

You may also be interested in...



Generic Drug Use To Increase In Japan

 

US Probiotics Market Stirs With Chobani Beverages, Danone, Sofar And Plexus Blends For Kids

Chobani introduces Chobani Probiotic, its first functional probiotics beverage to support digestive and immune health; Danone North America extends its Danimals children’s yogurt line with products to support immune system; and Plexus Worldwide and Sofar Americas roll out children’s probiotics.

Social Media Posts Showed Almost 1,500 Adverse Events, 53 Deaths Linked To Essure: FDA Report

Report quantifies social media posts describing adverse events involving the Essure contraceptive device, which was pulled from the market amid safety concerns.

UsernamePublicRestriction

Register

LL1129788

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel